Lupin drops on profit taking

Meanwhile, the S&P BSE Sensex was down 30.93 points or 0.15% at 19,959.25.

On BSE, 93,000 shares were traded in the counter as against average daily volume of 60,210 shares in the past one quarter.

The stock hit a high of Rs 738 and a low of Rs 718 so far during the day. The stock had hit a record high of Rs 738.80 on Wednesday, 8 May 2013. The stock had hit a 52-week low of Rs 507 on 15 June 2012.

The stock had outperformed the market over the past one month till 8 May 2013, jumping 18.06% compared with the Sensex's 8.42% surge. The scrip had also outperformed the market in past one quarter, surging 22.15% as against Sensex's 2.59% rise.

The large-cap company has equity capital of Rs 89.53 crore. Face value per share is Rs 2.

Shares of Lupin had risen 2.42% to settle at Rs 730.65 on Wednesday, 8 May 2013, after the company reported strong Q4 results. The stock had risen 4.54% in two trading sessions to settle at Rs 730.65 on Wednesday, 8 May 2013, from a recent low of Rs 698.90 on 6 May 2013.

Lupin's consolidated net profit surged 162.2% to Rs 408.10 crore on 34.7% increase in net sales to Rs 2537.40 crore in Q4 March 2013 over Q4 March 2012. Earnings before interest, tax, depreciation and amortization (EBITDA) spurted 74.5% to Rs 664.90 crore in Q4 March 2013 over Q4 March 2012.

Lupin's consolidated net profit rose 51.5% to Rs 1314.20 crore on 35.9% growth in net sales to Rs 9461.60 crore in the year ended 31 March 2013 (FY 2013) over the year ended 31 March 2012 (FY 2012).

Lupin is a pharmaceutical company producing and developing a wide range of branded and generic formulations and active pharmaceutical ingredients. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-infective and NSAID space and holds global leadership positions in the anti-TB and Cephalosporin segment.

Powered by Capital Market - Live News